Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China

Author:

Bing Xin12,Lei Huijun13ORCID,Zhao Xiaojiao12,Cheng Yongran4,Wang Liangyou5ORCID,Yang Jun2ORCID,Xu Mingzhi36,Yu Chenhuan13,Chen Tianhui137ORCID

Affiliation:

1. Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou 310022, China

2. School of Public Health, Hangzhou Normal University, Hangzhou 311121, China

3. Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China

4. School of Public Health, Hangzhou Medical College, Hangzhou 310013, China

5. Department of Non-Communicable Chronic Disease Control and Prevention, Taizhou Center for Disease Control and Prevention, Taizhou 318000, China

6. Department of General Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China

7. Department of Preventive Medicine, School of Medicine, Ningbo University, Ningbo 315211, China

Abstract

Objective: Ovarian cancer is a deadly gynecologic malignancy with a poor prognosis. It is essential to evaluate the early detection and screening programs of ovarian cancer via timely assessment of long-time survival, particularly in China where those data are incredibly limited. Here, we aimed to provide timely and accurately assessment of long-term survival estimate of ovarian cancer patients from eastern China. Methods: Data of 770 ovarian cancer patients diagnosed between 2004–2018 were obtained from four cancer registries in Taizhou, eastern China, were included. We used period analysis to calculate five-year relative survival (RS) of aforementioned ovarian cancer patients for overall and the stratification by age at diagnosis and region. Results: Our findings demonstrated that the overall five-year RS for ovarian cancer patients in Taizhou between 2014 and 2018 was 69.2%, while urban areas were higher compared to rural areas (77.6% vs. 64.9%). We also observed a significant age gradient with the five-year RS decreasing from 79.6% for age group < 55 years to 66.9% for age group > 74 years. Furthermore, we identified a clear upward trend of five-year RS over the study period, both overall and stratified by region and age at diagnosis. Conclusion: This is the first study in China using period analysis to provide the most up-to-date five-year RS for ovarian cancer patients from Taizhou, eastern China, which reaches 69.2% during 2014–2018. Our results provide valuable information for timely assessment of early detection and screening programs for ovarian cancer in eastern China.

Funder

National Key Research-Development Program of China

Natural Science Foundation of Zhejiang Province

Ten-Thousand Talents Plan of Zhejiang Province

Joint Key Program of Zhejiang Province-Ministry of Health

Publisher

MDPI AG

Subject

General Medicine

Reference41 articles.

1. Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018;Khazaei;J. Prev. Med. Hyg.,2021

2. The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia;Razi;Ecancermedicalscience,2016

3. Global Scenario on Ovarian Cancer—Its Dynamics, Relative Survival, Treatment, and Epidemiology;Saba;Adesh Univ. J. Med. Sci. Res.,2020

4. Eurocare Working Group Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade;Oberaigner;Acta Oncol.,2012

5. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clinic.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3